Researchers at the University of Calgary in Canada are conducting further trials after early studies revealed that vitamin B3, or niacin, holds promise in restoring immune function in the fight against glioblastoma, a brain cancer that grows aggressively and is hard to treat. The findings, which suggest niacin could be used alongside standard treatments like radiotherapy and chemotherapy, have sparked interest in the potential for combination therapies that may improve outcomes for patients.
Glioblastoma is one of the most aggressive forms of brain cancer, with a median survival rate of around 15 months despite intensive treatment. Current standard care includes surgical resection, radiation, and chemotherapy, but the tumor often recurs. The immune system's inability to effectively target cancer cells is a key challenge, and researchers have been exploring ways to reactivate immune responses. Early studies at the University of Calgary indicated that niacin, a B vitamin found in foods like meat, fish, and fortified grains, could help restore the function of immune cells called macrophages, which are often suppressed in glioblastoma.
It remains to be seen whether clinical studies involving larger numbers of patients confirm what these early studies have shown about the benefits of using niacin alongside radiotherapy and chemotherapy to boost treatment outcomes. If results are good, it could open the door to using combination treatments that include niacin and other future therapies from firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) indicated for glioblastoma and other cancers. CNS Pharmaceuticals is developing novel therapies for brain tumors, and a combination approach with niacin could potentially enhance efficacy.
The implications of this research extend beyond glioblastoma. If niacin proves effective in restoring immune function in this challenging cancer, it could pave the way for similar strategies in other cancers where immune suppression is a barrier. The vitamin's low cost and safety profile make it an attractive candidate for combination therapy, potentially increasing access to improved treatments. However, researchers caution that these are early findings and larger, randomized controlled trials are necessary to confirm efficacy and establish optimal dosing.
For now, patients are advised not to self-administer high doses of niacin without medical supervision, as excessive intake can cause side effects such as liver damage, flushing, and gastrointestinal issues. The University of Calgary team is recruiting participants for the next phase of trials, which will evaluate niacin in combination with standard therapy in a larger group of glioblastoma patients. The outcome of these studies could have significant implications for the field of neuro-oncology and beyond.
